Replies to post #102557 on Biotech Values

[DewDiligence]

WPI is US “front end” for generic-Revlimid attempt from India’s Natco Pharma:

http://finance.yahoo.com/news/Watson-Confirms-Development-prnews-233923578.html?x=0&.v=1

#msg-53738423 is a good background read on how CELG intends to maintain Revlimid exclusivity.

Natco is also the supplier of MYL’s knockoff of Copaxone for the US market (#msg-29902618, #msg-52598947).